Latest Proof Of Concept News

WA1 Resources has reported a significant milestone in its Luni Niobium Project with successful proof-of-concept niobium oxide refining testwork yielding a premium 96.8% Nb2O5 sample. The company also secured $100 million in a recent placement, bolstering its cash reserves to approximately $155 million.

icetana Limited reports its strongest quarterly growth yet, driven by a strategic partnership with SoftBank Robotics that has propelled annual recurring revenue to $2.3 million.

Nanoveu’s subsidiary EMASS has partnered with Arrow Electronics to accelerate the deployment of its ultra-low-power ECS-DoT edge AI chip, aiming to simplify always-on AI integration across multiple industries.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting genetic diseases, alongside a strong cash runway supporting ongoing development.

S2 Resources has ramped up exploration activities across multiple Australian projects, commencing diamond drilling at Warraweena and expanding ground at Jillewarra, while securing A$0.61 million through capital raisings and maintaining a robust cash position bolstered by a significant Valkea Resources investment.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.

Locksley Resources has produced the first 100% American made antimony ingot in decades, validating a fully domestic mine-to-metal supply chain and advancing U.S. critical minerals independence.

Kinetiko Energy and FFS Refiners have formalised a joint development agreement to co-develop a pilot LNG plant at Brakfontein, marking a significant step in South Africa’s energy transition. The initial phase involves co-funded drilling and gas testing with plans to scale LNG production substantially.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.